ORKA
Oruka Therapeutics, Inc.
$88.27
+3.87
(+4.59%)
Mkt Cap
3.31B
Volume
547,793
52W Range
12.84-97.78
Sector
Healthcare
Beta
-0.40
EPS (TTM)
-2.39
P/E Ratio
-13.12
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (105.43M) | (83.72M) | (5.34M) | (9.93M) | (19.32M) | (9.74M) | (5.48M) | (7.93M) | (18.49M) | (16.44M) | (11.45M) | (9.69M) |
| EPS | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 | -49.79 | -123.73 | -382.87 | -390.96 | -393.12 | -710.64 |
| Free Cash Flow | (88.42M) | (58.03M) | N/A | (10.91M) | (18.80M) | (7.74M) | (4.80M) | (8.25M) | (17.48M) | (15.00M) | (10.54M) | (9.43M) |
| FCF / Share | -1.94 | -3.46 | N/A | -0.76 | -1.35 | -1.64 | -43.64 | -128.64 | -361.85 | -357.31 | -362.16 | -695.11 |
| Operating CF | (88.21M) | (57.84M) | N/A | (10.91M) | (18.76M) | (7.72M) | (4.80M) | (8.24M) | (17.47M) | (14.99M) | (10.53M) | (9.41M) |
| Total Assets | 488.62M | 396.02M | 37.86M | 43.09M | 54.92M | 50.43M | 8.54M | 6.83M | 12.37M | 24.63M | 39.57M | 16.13M |
| Total Debt | 1.93M | 968,000 | 280,000 | 383,000 | 483,000 | 450,000 | 25,000 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 46.94M | 61.58M | 37.43M | 42.45M | 53.36M | 49.07M | 8.36M | 6.61M | 8.70M | 7.40M | 38.80M | 15.35M |
| Book Value | 471.93M | 382.22M | 37.02M | 41.67M | 51.04M | 46.52M | 7.61M | 6.03M | 10.28M | 22.19M | 38.07M | 14.74M |
| Return on Equity | -0.22 | -0.22 | -0.14 | -0.24 | -0.38 | -0.21 | -0.72 | -1.32 | -1.80 | -0.74 | -0.30 | -0.66 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (31.82M) | (29.58M) | (30.28M) | (24.57M) | (21.00M) | (33.39M) | (28.62M) | (22.24M) | (2.01M) | (1.09M) | (1.42M) | (1.48M) |
| EPS | -0.58 | -0.54 | -0.69 | -0.58 | -0.50 | -1.54 | -1.91 | -1.30 | -0.24 | -0.90 | -1.19 | -1.23 |
| Free Cash Flow | (23.65M) | (22.66M) | (21.70M) | (23.18M) | (20.88M) | (18.84M) | (35.03M) | (2.63M) | (168,000) | N/A | N/A | N/A |
| FCF / Share | -0.43 | -0.42 | -0.49 | -0.55 | -0.50 | -1.12 | -2.33 | -0.18 | -0.01 | N/A | N/A | N/A |
| Operating CF | (23.58M) | (22.59M) | (21.60M) | (23.14M) | (20.87M) | (18.82M) | (34.86M) | (2.63M) | (168,000) | N/A | N/A | N/A |
| Total Assets | 504.48M | 488.62M | 509.25M | 357.42M | 377.11M | 396.02M | 414.09M | 33.84M | 36.71M | 37.86M | 39.18M | 41.08M |
| Total Debt | 1.81M | 1.93M | 1.91M | 2.33M | 947,000 | 968,000 | 988,000 | 24,000 | 48,000 | 280,000 | 301,000 | 329,000 |
| Cash & Equiv | 49.52M | 46.94M | 91.25M | 65.40M | 83.57M | 61.58M | 410.88M | 33.28M | 35.90M | 37.43M | 38.49M | 40.16M |
| Book Value | 486.72M | 471.93M | 486.79M | 343.64M | 364.73M | 382.22M | 342.37M | 32.57M | 35.12M | 37.02M | 37.97M | 39.24M |
| Return on Equity | -0.07 | -0.06 | -0.06 | -0.07 | -0.06 | -0.09 | -0.08 | -0.68 | -0.06 | -0.03 | -0.04 | -0.04 |
ORKA News
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing